SCHEMBL35210830

SCHEMBL35210830

NCOC(=O)N1CCC(F)(F)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DPP4 P27487 2/20 0.34
DPP7 Q9UHL4 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
EPHX2 P34913 1/20 0.33
RECQL P46063 1/20 0.33
NOS3 P29474 3/20 0.32
NOS2 P35228 3/20 0.32
NOS1 P29475 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20641603 0.82 CYP2D6 (0.44) L3MBTL1GAACYP2D6TSHRALDH1A1
SCHEMBL5986980 0.82 TSHR (0.53) L3MBTL1GAATSHRALDH1A1KDM4E
SCHEMBL25226762 0.77
SCHEMBL21722375 0.77 ALDH1A1 (0.42) L3MBTL1GAATSHRALDH1A1KDM4E
SCHEMBL20101964 0.77 LMNA (0.44) L3MBTL1CYP2D6TSHRALDH1A1POLB
SCHEMBL13724361 0.75 ALDH1A1 (0.45) L3MBTL1GAATSHRALDH1A1KDM4E
SCHEMBL3632294 0.74 CYP1A2 (0.56) CYP2D6TSHRALDH1A1CYP1A2CYP2C9
SCHEMBL3632291 0.74 CYP1A2 (0.36) CYP2D6DPP4DPP7CYP1A2CYP2C9
Hydrochloric Acid SCHEMBL20570929 0.74 ALDH1A1 (0.44) L3MBTL1GAATSHRALDH1A1KDM4E
SCHEMBL29194335 0.72 CA2 (0.43) GAATSHRALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, GMPS, PRKG1 L3MBTL1 1687/4885GAA 163/4885CYP2D6 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.